

**Top 25 Products Ranked By Paid Amount of FFS Claims, Summary Report for the  
4th Quarter 2022 (April, May, and June)**

| HICL  | HICL Description   | Rank | Paid            | Claims | PUPM        | 3rd Q22 Rank | 2nd Q22 Rank | 1st Q22 Rank | 4th Q21 Rank |
|-------|--|------|-----------------|--------|-------------|--------------|--------------|--------------|--------------|
| 24800 | adalimumab   | 1    | \$21,133,105.43 | 2,722  | \$10,289.76 | 1            | 1            | 1            | 1            |
| 36479 | paliperidone palmitate                                       | 2    | \$14,753,479.91 | 5,316  | \$3,391.05  | 2            | 2            | 2            | 2            |
| 37321 | lurasidone HCl   | 3    | \$11,614,591.48 | 9,372  | \$1,668.33  | 3            | 3            | 3            | 3            |
| 44765 | bictegravir sodium/emtricitabine/tenofovir alafenamide fumar | 4    | \$9,647,211.48  | 3,219  | \$3,514.19  | 7            | 10           | 13           | 16           |
| 1682  | methylphenidate HCl  | 5    | \$9,397,287.24  | 33,287 | \$354.47    | 5            | 4            | 5            | 4            |
| 46112 | elexacaftor/tezacaftor/ivacaftor                             | 6    | \$9,251,283.68  | 455    | \$27,534.58 | 4            | 5            | 4            | 8            |
| 44453 | glecaprevir/pibrentasvir                                     | 7    | \$8,624,508.05  | 589    | \$10,493.10 | 10           | 14           | 22           | n/a          |
| 20769 | insulin aspart   | 8    | \$8,294,605.51  | 12,415 | \$631.77    | 6            | 6            | 6            | 5            |
| 22025 | insulin glargine,human recombinant analog                    | 9    | \$7,439,213.37  | 16,355 | \$429.28    | 8            | 8            | 8            | 6            |
| 2073  | albuterol sulfate  | 10   | \$7,253,386.12  | 97,162 | \$68.18     | 9            | 7            | 7            | 7            |
| 21993 | budesonide/formoterol fumarate                               | 11   | \$6,939,177.60  | 19,032 | \$363.78    | 11           | 9            | 9            | 9            |
| 42552 | cariprazine HCl  | 12   | \$6,849,383.09  | 6,193  | \$1,385.27  | 12           | 11           | 11           | 13           |
| 41421 | dulaglutide  | 13   | \$6,325,136.65  | 7,774  | \$1,008.51  | n/a          | n/a          | n/a          | n/a          |
| 41369 | pembrolizumab  | 14   | \$6,051,497.08  | 709    | \$11,375.99 | 15           | 17           | 15           | 17           |
| 34486 | lisdexamfetamine dimesylate                                  | 15   | \$5,612,201.28  | 17,247 | \$377.71    | 13           | 12           | 12           | 12           |
| 44640 | emicizumab-kxwh  | 16   | \$5,504,810.51  | 181    | \$52,931.87 | 16           | 15           | 20           | 22           |
| 36436 | liraglutide  | 17   | \$5,437,905.97  | 5,804  | \$1,022.78  | 14           | 13           | 10           | 14           |
| 24551 | aripiprazole   | 18   | \$4,972,212.74  | 31,802 | \$201.90    | 17           | 19           | 18           | 20           |
| 24846 | buprenorphine HCl/naloxone HCl                               | 19   | \$4,875,207.62  | 15,627 | \$558.68    | 18           | 18           | 17           | 18           |
| 7873  | fluticasone propionate                                       | 20   | \$4,763,252.40  | 60,870 | \$63.45     | 19           | 16           | 14           | 15           |
| 36187 | ustekinumab  | 21   | \$4,396,748.62  | 242    | \$16,047.53 | 21           | 23           | 25           | 25           |
| 24024 | tiotropium bromide   | 22   | \$4,329,624.43  | 9,141  | \$543.56    | 20           | 20           | 19           | 19           |
| 37792 | apixaban   | 23   | \$4,153,764.11  | 9,702  | \$541.01    | 22           | n/a          | n/a          | n/a          |
| 2824  | somatropin   | 24   | \$4,131,194.06  | 1,381  | \$4,051.19  | 24           | 21           | 16           | 10           |
| 18830 | etanercept   | 25   | \$4,095,719.08  | 732    | \$7,014.22  | n/a          | n/a          | 24           | 24           |

**Top 25 Products Ranked By Paid Number of FFS Claims, Summary Report for the  
4th Quarter 2022 (April, May, and June)**

| HICL  | HICL Description                     | Rank | Paid           | Claims | PUPM     | 3rd Q22 Rank | 2nd Q22 Rank | 1st Q22 Rank | 4th Q21 Rank |
|-------|--------------------------------------|------|----------------|--------|----------|--------------|--------------|--------------|--------------|
| 02073 | albuterol sulfate                    | 1    | \$7,253,386.12 | 97,162 | \$68.18  | 1            | 1            | 1            | 1            |
| 12404 | atorvastatin calcium                 | 2    | \$946,120.02   | 69,640 | \$18.09  | 3            | 4            | 4            | 5            |
| 08831 | gabapentin                           | 3    | \$1,171,354.18 | 68,183 | \$22.31  | 2            | 2            | 3            | 3            |
| 07873 | fluticasone propionate               | 4    | \$4,763,252.40 | 60,870 | \$63.45  | 4            | 6            | 5            | 4            |
| 06324 | sertraline HCl                       | 5    | \$755,117.05   | 56,468 | \$16.78  | 5            | 7            | 6            | 6            |
| 00132 | lisinopril                           | 6    | \$664,375.96   | 56,261 | \$15.76  | 6            | 8            | 8            | 9            |
| 04673 | omeprazole                           | 7    | \$740,420.22   | 54,529 | \$16.76  | 7            | 9            | 7            | 8            |
| 06544 | cetirizine HCl                       | 8    | \$704,425.77   | 51,825 | \$9.31   | 12           | 5            | 2            | 2            |
| 01652 | trazodone HCl                        | 9    | \$658,130.85   | 50,753 | \$16.45  | 8            | 10           | 9            | 11           |
| 04763 | metformin HCl                        | 10   | \$612,588.67   | 50,133 | \$15.77  | 9            | 13           | 13           | 14           |
| 03963 | amoxicillin                          | 11   | \$713,497.77   | 50,030 | \$8.71   | 10           | 3            | 10           | 12           |
| 02849 | levothyroxine sodium                 | 12   | \$650,688.03   | 48,022 | \$19.18  | 11           | 12           | 12           | 13           |
| 06494 | amlodipine besylate                  | 13   | \$550,531.54   | 47,958 | \$15.06  | 13           | 15           | 15           | 16           |
| 08255 | 0.9 % sodium chloride                | 14   | \$195,088.42   | 46,768 | \$4.92   | 17           | 16           | 16           | 20           |
| 03723 | ibuprofen                            | 15   | \$517,132.79   | 45,073 | \$8.43   | 14           | 11           | 11           | 15           |
| 22008 | pantoprazole sodium                  | 16   | \$677,407.35   | 44,419 | \$18.46  | 15           | 18           | 19           | 18           |
| 16911 | montelukast sodium                   | 17   | \$650,528.59   | 42,979 | \$17.17  | 18           | 14           | 17           | 10           |
| 01655 | fluoxetine HCl                       | 18   | \$602,382.87   | 42,207 | \$18.59  | 16           | 17           | 20           | 21           |
| 01730 | hydrocodone bitartrate/acetaminophen | 19   | \$621,007.27   | 37,880 | \$16.09  | 19           | 19           | 21           | 19           |
| 01608 | hydroxyzine HCl                      | 20   | \$540,703.32   | 35,456 | \$15.14  | 22           | 23           | n/a          | n/a          |
| 01653 | bupropion HCl                        | 21   | \$699,430.93   | 35,221 | \$24.64  | 24           | n/a          | n/a          | n/a          |
| 24022 | escitalopram oxalate                 | 22   | \$485,892.14   | 34,508 | \$17.31  | 25           | n/a          | n/a          | n/a          |
| 01682 | methylphenidate HCl                  | 23   | \$9,397,287.24 | 33,287 | \$354.47 | 20           | 20           | 23           | 22           |
| 00113 | clonidine HCl                        | 24   | \$448,550.81   | 32,920 | \$18.09  | 21           | 21           | 22           | 25           |
| 01620 | bupirone HCl                         | 25   | \$473,627.14   | 32,537 | \$17.54  | n/a          | n/a          | n/a          | n/a          |

**MO HealthNet New Drug Summary - August 2022**

| DRUG                           | Approved | Denied | Pending | Total |
|--------------------------------|----------|--------|---------|-------|
| AEMCOLO DR 194 MG TABLET       | 0        | 0      | 1       | 1     |
| ALDURAZYME 2.9 MG/5 ML VIAL    | 1        | 0      | 0       | 1     |
| APRETUDE ER 600 MG/3 ML VIAL   | 0        | 0      | 1       | 1     |
| AZSTARYS 26.1 MG-5.2 MG CAP    | 0        | 0      | 2       | 2     |
| AZSTARYS 39.2 MG-7.8 MG CAP    | 0        | 0      | 1       | 1     |
| BACLOFEN 5 MG/5 ML SOLUTION    | 1        | 0      | 0       | 1     |
| CAMZYOS 5 MG CAPSULE           | 1        | 0      | 1       | 2     |
| CAPLYTA 21 MG CAPSULE          | 0        | 0      | 5       | 5     |
| CITALOPRAM HBR 30 MG CAPSULE   | 0        | 0      | 3       | 3     |
| FLEQSUVY 25 MG/5 ML SUSPENSION | 3        | 0      | 1       | 4     |
| IBSRELA 50 MG TABLET           | 1        | 0      | 3       | 4     |
| INJECTAFER 100 MG/2 ML VIAL    | 1        | 0      | 3       | 4     |
| INSULIN GLARGINE-YFGN U100 PEN | 0        | 0      | 5       | 5     |
| INSULIN GLARGINE-YFGN U100 VL  | 0        | 0      | 1       | 1     |
| LEQVIO 284 MG/1.5 ML SYRINGE   | 1        | 0      | 3       | 4     |
| LYVISPAH 5 MG GRANULE PACKET   | 1        | 0      | 2       | 3     |
| MOUNJARO 12.5 MG/0.5 ML PEN    | 0        | 0      | 1       | 1     |
| MOUNJARO 2.5 MG/0.5 ML PEN     | 1        | 0      | 20      | 21    |
| MOUNJARO 5 MG/0.5 ML PEN       | 0        | 0      | 10      | 10    |
| MOUNJARO 7.5 MG/0.5 ML PEN     | 0        | 0      | 1       | 1     |
| OXBRYTA 300 MG TABLET FOR SUSP | 1        | 0      | 2       | 3     |
| OZEMPIC 2 MG/DOSE (8 MG/3 ML)  | 2        | 0      | 16      | 18    |
| PEGASYS 180 MCG/ML VIAL        | 0        | 0      | 1       | 1     |
| QULIPTA 10 MG TABLET           | 0        | 0      | 3       | 3     |
| QULIPTA 30 MG TABLET           | 0        | 0      | 5       | 5     |
| QULIPTA 60 MG TABLET           | 1        | 0      | 15      | 16    |
| QUVIVIQ 50 MG TABLET           | 0        | 0      | 3       | 3     |
| SEMGLEE (YFGN) 100 UNIT/ML PEN | 0        | 0      | 1       | 1     |
| SKYRIZI 150 MG/ML PEN          | 1        | 0      | 10      | 11    |
| SKYRIZI 150 MG/ML SYRINGE      | 1        | 1      | 1       | 3     |
| SKYRIZI 360 MG/2.4 ML ON-BODY  | 0        | 0      | 1       | 1     |
| SKYRIZI 600 MG/10 ML VIAL      | 1        | 0      | 5       | 6     |
| SKYTROFA 9.1 MG CARTRIDGE      | 0        | 1      | 1       | 2     |
| STRENSIQ 80 MG/0.8 ML VIAL     | 1        | 0      | 0       | 1     |
| TAKHZYRO 300 MG/2 ML SYRINGE   | 1        | 0      | 1       | 2     |
| TEZSPIRE 210 MG/1.91 ML SYRING | 4        | 0      | 12      | 16    |
| TRIUMEQ PD 60-5-30 MG TAB SUSP | 1        | 0      | 1       | 2     |
| TWYNEO 0.1%-3% CREAM           | 0        | 0      | 1       | 1     |
| TYVASO DPI 32-48 MCG MAINT KIT | 0        | 0      | 1       | 1     |
| TYVASO DPI 64 MCG CARTRIDGE    | 1        | 0      | 0       | 1     |
| VIJOICE 250 MG DAILY DOSE PACK | 0        | 0      | 2       | 2     |
| VYVGART 400 MG/20 ML VIAL      | 1        | 0      | 5       | 6     |
| XARELTO 1 MG/ML SUSPENSION     | 1        | 0      | 4       | 5     |



SUBJECT: August 1, 2022 - August 31, 2022

**State of Missouri Medicaid**  
*Conduent™ CyberAccess Helpdesk Status Report*

**CLINICAL EDIT/PRIOR AUTHORIZATION PROGRAM OVERVIEW**

| Helpdesk Transactions                    | Total        |
|--|--------------|
| <i>Total Helpdesk Transaction Count</i>  | <b>7,805</b> |
| <i>Total Approved Claims at Helpdesk</i> | <b>7,788</b> |
| <i>Total Denied Claims at Helpdesk</i>   | <b>17</b>    |

**CLINICAL EDIT/PRIOR AUTHORIZATION TRANSACTION COUNTS**

| Drug Class                  | Helpdesk | Helpdesk Denied | Helpdesk Total |
|-----------------------------|----------|-----------------|----------------|
| <i>ACEIS DIURETIC COMBO</i> | 3        | 0               | 3              |
| <i>Acne and Rosacea</i>     | 9        | 0               | 9              |
| <i>ACTIN KERATOSIS TOP</i>  | 6        | 0               | 6              |
| <i>ADHD</i>                 | 530      | 2               | 532            |
| <i>ADHD AMPHET LA</i>       | 173      | 0               | 173            |
| <i>ADHD AMPHET SA</i>       | 79       | 0               | 79             |
| <i>ADHD METHYL LA</i>       | 152      | 0               | 152            |
| <i>ADHD METHYL SA</i>       | 56       | 0               | 56             |
| <i>ADHD NON STIM</i>        | 196      | 0               | 196            |
| <i>ALZHEIMERS AGENTS</i>    | 1        | 0               | 1              |
| <i>Ampyra</i>               | 1        | 0               | 1              |
| <i>ANTIBIOTIC MUPIROCIN</i> | 2        | 0               | 2              |
| <i>ANTIBIOTICS GI ORAL</i>  | 57       | 0               | 57             |
| <i>ANTIBIOTICS INHALED</i>  | 3        | 0               | 3              |
| <i>ANTIBIOTICS VAGINAL</i>  | 7        | 0               | 7              |
| <i>ANTICHOL LA INHALED</i>  | 1        | 0               | 1              |
| <i>ANTICHOL LABA COMBOS</i> | 15       | 0               | 15             |
| <i>ANTICHOL LABA ICS PD</i> | 27       | 1               | 28             |
| <i>ANTICOAGULANTS</i>       | 8        | 0               | 8              |
| <i>ANTICONVUL DRAVET</i>    | 8        | 0               | 8              |
| <i>ANTICONVUL RESCUE</i>    | 16       | 0               | 16             |
| <i>ANTIEMETIC 5HT3 INJ</i>  | 5        | 0               | 5              |
| <i>ANTIEMETIC 5HT3 NONI</i> | 9        | 0               | 9              |
| <i>ANTIFUNGALS ORAL</i>     | 11       | 0               | 11             |
| <i>ANTIFUNGALS TOPICAL</i>  | 1        | 0               | 1              |
| <i>ANTIHISTAMINES 2ND G</i> | 39       | 0               | 39             |
| <i>ANTIHISTAMINES OPHTH</i> | 3        | 0               | 3              |

|                                       |            |          |            |
|---------------------------------------|------------|----------|------------|
| <b>ANTIHYPERURICEMIC AG</b>           | <b>9</b>   | <b>0</b> | <b>9</b>   |
| <b>ANTIMIGRAINE ALTORAL</b>           | <b>81</b>  | <b>0</b> | <b>81</b>  |
| <b>ANTIMIGRAINE TRIPTAN</b>           | <b>77</b>  | <b>0</b> | <b>77</b>  |
| <b>ANTIPARKIN NON ERGOT</b>           | <b>2</b>   | <b>0</b> | <b>2</b>   |
| <b>ANTIPLATELETS</b>                  | <b>5</b>   | <b>0</b> | <b>5</b>   |
| <b>Antipsychotics 1st gen Typical</b> | <b>131</b> | <b>0</b> | <b>131</b> |
| <b>Antipsychotics 2nd gen Atypica</b> | <b>909</b> | <b>3</b> | <b>912</b> |
| <b>ANTIRETROVIRAL</b>                 | <b>47</b>  | <b>1</b> | <b>48</b>  |
| <b>ANTIVIRALS HERPES OR</b>           | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>APAP Accumulation</b>              | <b>296</b> | <b>0</b> | <b>296</b> |
| <b>ARB CCB COMBOS</b>                 | <b>2</b>   | <b>0</b> | <b>2</b>   |
| <b>ARB DIURETIC COMBOS</b>            | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>ATOPIC DERMATITIS</b>              | <b>9</b>   | <b>0</b> | <b>9</b>   |
| <b>Benzodiazepines SelectOral</b>     | <b>736</b> | <b>0</b> | <b>736</b> |
| <b>BENZYL PER ANTIBI CM</b>           | <b>6</b>   | <b>0</b> | <b>6</b>   |
| <b>BETA ADRENERGIC-LONG</b>           | <b>7</b>   | <b>0</b> | <b>7</b>   |
| <b>BETA ADRENERGIC-NEBU</b>           | <b>15</b>  | <b>0</b> | <b>15</b>  |
| <b>BETA ADRENERGIC-SHOR</b>           | <b>24</b>  | <b>0</b> | <b>24</b>  |
| <b>BETA BLOCKERS</b>                  | <b>13</b>  | <b>0</b> | <b>13</b>  |
| <b>BiDil</b>                          | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>BIGUANIDES</b>                     | <b>7</b>   | <b>0</b> | <b>7</b>   |
| <b>BILE SALT AGENTS</b>               | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>Biosim vs Refer</b>                | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>Botox</b>                          | <b>50</b>  | <b>0</b> | <b>50</b>  |
| <b>CCB - DHP</b>                      | <b>2</b>   | <b>0</b> | <b>2</b>   |
| <b>CDK4/6 INHIBITORS</b>              | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>CEPHALOSPORIN</b>                  | <b>8</b>   | <b>0</b> | <b>8</b>   |
| <b>CFTR</b>                           | <b>17</b>  | <b>0</b> | <b>17</b>  |
| <b>CGRP INHIBITORS</b>                | <b>117</b> | <b>0</b> | <b>117</b> |
| <b>Corlanor</b>                       | <b>5</b>   | <b>0</b> | <b>5</b>   |
| <b>CORTICOSTERO INHALED</b>           | <b>13</b>  | <b>0</b> | <b>13</b>  |
| <b>CORTICOSTERO INTRANA</b>           | <b>19</b>  | <b>0</b> | <b>19</b>  |
| <b>CORTICOSTERO TOPICAL</b>           | <b>5</b>   | <b>0</b> | <b>5</b>   |
| <b>Crysvita</b>                       | <b>4</b>   | <b>0</b> | <b>4</b>   |
| <b>Diabetic Supplies</b>              | <b>2</b>   | <b>0</b> | <b>2</b>   |
| <b>Diabetic Supply Qty Lmt</b>        | <b>9</b>   | <b>0</b> | <b>9</b>   |
| <b>DRY EYE DISEASE</b>                | <b>2</b>   | <b>0</b> | <b>2</b>   |
| <b>ELECT DEPL PHOSPHATE</b>           | <b>6</b>   | <b>0</b> | <b>6</b>   |
| <b>ELECT DEPL POTASSIUM</b>           | <b>6</b>   | <b>0</b> | <b>6</b>   |
| <b>Entresto</b>                       | <b>31</b>  | <b>0</b> | <b>31</b>  |
| <b>EPINEPHRINE SELF INJ</b>           | <b>4</b>   | <b>0</b> | <b>4</b>   |
| <b>ERYTHRO STIM AGENTS</b>            | <b>2</b>   | <b>0</b> | <b>2</b>   |
| <b>FIBROMYALGIA</b>                   | <b>356</b> | <b>0</b> | <b>356</b> |
| <b>FLUROQUINOLONE OPTH</b>            | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>FLUROQUINOLONES</b>                | <b>35</b>  | <b>0</b> | <b>35</b>  |
| <b>FLUROQUINOLONE OTIC</b>            | <b>11</b>  | <b>0</b> | <b>11</b>  |
| <b>GENERIC OVERRIDES</b>              | <b>1</b>   | <b>0</b> | <b>1</b>   |

|                               |            |          |            |
|-------------------------------|------------|----------|------------|
| <b>GH SOMATROPIN AGENTS</b>   | <b>62</b>  | <b>4</b> | <b>66</b>  |
| <b>GI MOTILITY</b>            | <b>184</b> | <b>0</b> | <b>184</b> |
| <b>GLAUCOMA AGENTS</b>        | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>GLP-1 RECEPTOR AGONI</b>   | <b>342</b> | <b>0</b> | <b>342</b> |
| <b>GLUCAGON AGENTS</b>        | <b>2</b>   | <b>0</b> | <b>2</b>   |
| <b>GnRH Antagonists Oral</b>  | <b>5</b>   | <b>0</b> | <b>5</b>   |
| <b>HEPATITIS C</b>            | <b>8</b>   | <b>0</b> | <b>8</b>   |
| <b>HEREDITARY ANGIOEDEM</b>   | <b>2</b>   | <b>0</b> | <b>2</b>   |
| <b>Immunoglobulins</b>        | <b>8</b>   | <b>0</b> | <b>8</b>   |
| <b>INSULINS - LONG ACTI</b>   | <b>35</b>  | <b>0</b> | <b>35</b>  |
| <b>INSULINS - RAPID ACT</b>   | <b>27</b>  | <b>0</b> | <b>27</b>  |
| <b>INSULINS NON ANALOGS</b>   | <b>7</b>   | <b>0</b> | <b>7</b>   |
| <b>Iron Injectable</b>        | <b>4</b>   | <b>0</b> | <b>4</b>   |
| <b>Kerendia</b>               | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>LEUKOTRIENE</b>            | <b>116</b> | <b>0</b> | <b>116</b> |
| <b>LHRH GNRH NON ORAL</b>     | <b>7</b>   | <b>0</b> | <b>7</b>   |
| <b>MACROLIDES</b>             | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>Megestrol</b>              | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>METHOTREXATE ORAL_IN</b>   | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>Misoprostol</b>            | <b>13</b>  | <b>0</b> | <b>13</b>  |
| <b>MME</b>                    | <b>112</b> | <b>0</b> | <b>112</b> |
| <b>MULT SCLEROSIS INJ</b>     | <b>12</b>  | <b>1</b> | <b>13</b>  |
| <b>MULT SCLEROSIS ORAL</b>    | <b>4</b>   | <b>0</b> | <b>4</b>   |
| <b>Narcolepsy</b>             | <b>16</b>  | <b>0</b> | <b>16</b>  |
| <b>NEUROPATHIC PAIN</b>       | <b>255</b> | <b>0</b> | <b>255</b> |
| <b>New Drug - Missouri</b>    | <b>28</b>  | <b>2</b> | <b>30</b>  |
| <b>Non-Oral Contraceptive</b> | <b>39</b>  | <b>0</b> | <b>39</b>  |
| <b>NSAIDS</b>                 | <b>42</b>  | <b>0</b> | <b>42</b>  |
| <b>Nuedexta</b>               | <b>4</b>   | <b>0</b> | <b>4</b>   |
| <b>OPIOID ALCOHOL DEPEN</b>   | <b>47</b>  | <b>0</b> | <b>47</b>  |
| <b>OPIOID EMERG REV AG</b>    | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>OPIOIDS LONG ACTING</b>    | <b>49</b>  | <b>0</b> | <b>49</b>  |
| <b>OPIOIDS SHORT ACTING</b>   | <b>2</b>   | <b>0</b> | <b>2</b>   |
| <b>Oxandrin</b>               | <b>2</b>   | <b>0</b> | <b>2</b>   |
| <b>Oxazolidinones</b>         | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>PA Required</b>            | <b>58</b>  | <b>0</b> | <b>58</b>  |
| <b>PAH ETRAS</b>              | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>PAH PDE5 SGC</b>           | <b>3</b>   | <b>0</b> | <b>3</b>   |
| <b>PAH PROST INHALED</b>      | <b>1</b>   | <b>0</b> | <b>1</b>   |
| <b>PAH PROST ORAL</b>         | <b>7</b>   | <b>0</b> | <b>7</b>   |
| <b>PCSK9 INHIBITORS</b>       | <b>29</b>  | <b>0</b> | <b>29</b>  |
| <b>PPI</b>                    | <b>67</b>  | <b>0</b> | <b>67</b>  |
| <b>PSORIASIS AGNTS TOPI</b>   | <b>2</b>   | <b>0</b> | <b>2</b>   |
| <b>PTH Bone Resorp</b>        | <b>25</b>  | <b>0</b> | <b>25</b>  |
| <b>Ranexa</b>                 | <b>3</b>   | <b>0</b> | <b>3</b>   |
| <b>Rare Disease</b>           | <b>20</b>  | <b>0</b> | <b>20</b>  |
| <b>RETINOIDS TOPICAL</b>      | <b>47</b>  | <b>0</b> | <b>47</b>  |

|                             |     |   |     |
|-----------------------------|-----|---|-----|
| <i>RMAS</i>                 | 52  | 1 | 53  |
| <i>SEDATIVE HYPNOTICS</i>   | 197 | 0 | 197 |
| <i>SGLT2 INHIBITORS</i>     | 1   | 0 | 1   |
| <i>Sickle Cell Disease</i>  | 4   | 0 | 4   |
| <i>SKELETAL MUSCLE RELA</i> | 3   | 0 | 3   |
| <i>SNRI</i>                 | 217 | 1 | 218 |
| <i>Spravato</i>             | 17  | 0 | 17  |
| <i>SSRI</i>                 | 616 | 0 | 616 |
| <i>STATINS-HMG COA REDU</i> | 7   | 0 | 7   |
| <i>SYMPATHOLYTIC ANTIHY</i> | 123 | 0 | 123 |
| <i>Synagis</i>              | 27  | 1 | 28  |
| <i>Systemic Antifungals</i> | 12  | 0 | 12  |
| <i>TETRACYCLINES</i>        | 6   | 0 | 6   |
| <i>THIAZOLIDINEDIONES</i>   | 2   | 0 | 2   |
| <i>THROMBOCYTOPENIA</i>     | 7   | 0 | 7   |
| <i>TIMS IL17</i>            | 10  | 0 | 10  |
| <i>TIMS IL23-12</i>         | 13  | 0 | 13  |
| <i>TIMS IL6</i>             | 4   | 0 | 4   |
| <i>TIMS JAK</i>             | 10  | 0 | 10  |
| <i>TIMS SELECT</i>          | 16  | 0 | 16  |
| <i>TIMS TNFI</i>            | 54  | 0 | 54  |
| <i>Tolvaptan</i>            | 2   | 0 | 2   |
| <i>TRAMADOL LIKE AGENTS</i> | 77  | 0 | 77  |
| <i>TRIGLYCERIDE LOWERIN</i> | 23  | 0 | 23  |
| <i>ULCERATIVE COLITIS O</i> | 1   | 0 | 1   |
| <i>URINARY TRACT ANTISP</i> | 20  | 0 | 20  |
| <i>VMAT2 INHIBITORS</i>     | 45  | 0 | 45  |
| <i>Xcopri</i>               | 7   | 0 | 7   |
| <i>Zometa</i>               | 4   | 0 | 4   |

| <b>Utilization Indicators</b>                 | <b>Total</b> |
|---|--------------|
| <i>Average number of transactions per day</i> | 252          |

| <b>EARLY REFILL, DOSE OPTIMIZATION, HOSPICE, 15-DAY LIMITATION, AND</b> |              |
|---|--------------|
| <b>Helpdesk Transactions</b>  | <b>Total</b> |
| <i>Total Helpdesk Transaction Count</i>                                 | 2,793        |
| <i>Total Approved Claims at Helpdesk</i>                                | 2,783        |
| <i>Total Denied Claims at Helpdesk</i>                                  | 10           |
| <i>Total number of transactions completed by InfoX PA staff</i>         | 1,167        |
| <i>Total number of transactions completed by the State PA staff</i>     | 45           |

| <b>Early Refill</b>                        | <b>Total</b> |
|--|--------------|
| <i>Early Refill Authorization Requests</i> | 2,442        |
| <i>Early Refill Approvals</i>              | 2,344        |

|  |       |
|--|-------|
| <i>Approvals Due to Vacation Supply</i>      | 222   |
| <i>Approvals Due to Lost Prescription</i>    | 804   |
| <i>Approvals Due to Therapy Change</i>       | 1,022 |
| <i>Approvals Due to Starter Dose</i>         | 1     |
| <i>Approvals Due to Medically Necessary</i>  | 295   |
| <i>Early Refill Administrative Approvals</i> | 89    |
| <i>Early Refill Denials</i>                  | 9     |

| <b>Dose Optimization</b>                        | <b>Total</b> |
|---|--------------|
| <i>Dose Optimization Authorization Requests</i> | 221          |
| <i>Dose Optimization Approvals</i>              | 220          |
| <i>Dose Optimization Denials</i>                | 1            |

| <b>Exception 716 Override</b>              | <b>Total</b> |
|--|--------------|
| <i>Drug Approval for larger quantities</i> | 14           |
| <i>Drug Denial for larger quantities</i>   | 0            |

| <b>Exception 713 Override</b>                          | <b>Total</b> |
|--|--------------|
| <i>Drug Not Related to Terminal Illness - Approved</i> | 22           |
| <i>Drug Related to Terminal Illness - Denied</i>       | 0            |

| <b>Exception 712 Override</b>                 | <b>Total</b> |
|---|--------------|
| <i>Drug Therapy Approved for &gt; 15 Days</i> | 26           |
| <i>Drug Therapy Denied for &gt; 15 Days</i>   | 0            |

| <b>Early Refill, Dose Optimization, Exceptions 716, 713, and 712 Utilization Indicators</b> | <b>Total</b> |
|---|--------------|
| <i>Average number of transactions per day</i>   | 90.1         |
| <i>Override approval rate for ER and Dose Opt edits</i>                                     | 100%         |